April 23, 2012 -- New guidelines may help people with frequent migraine headaches get their lives back on track.
The migraine prevention guidelines will be presented at the American Academy of Neurology's annual meeting in New Orleans and published simultaneously in the journal Neurology.
About 36 million people in the U.S. have migraine headaches, according to the Migraine Research Foundation. Migraines are painful, often disabling headaches that may be accompanied by nausea, vomiting, and sensitivity to light.
For some, migraines are few and far between and respond well to available treatments. Others experience more frequent headaches that interfere with their life and don't respond well to treatments. The latter group may be candidates for the preventive treatments outlined in the guidelines. Preventive treatments usually are taken every day to prevent attacks from occurring as often and to lessen their severity and duration when they do occur.
About 38% of people with migraine headaches could benefit from prevention, but less than a third of them use them, says guideline author Stephen D. Silberstein, MD, of Jefferson Headache Center at Thomas Jefferson University in Philadelphia, in a news release. Researchers analyzed studies on migraine prevention treatments to determine which are or are not effective.
The anti-seizure drug Lamictal (lamotrigine) is not effective in preventing migraine, the guidelines state.
Certain nonsteroidal anti-inflammatory drugs (NSAIDS) and complementary therapies can also help prevent migraine headache. These include:
Petasites, an herb also known as butterbur
NSAIDs including fenoprofen, ibuprofen, ketoprofen, naproxen, and naproxen sodium
Histamine shots, which are a common allergy/asthma treatment
Magnesium, a mineral
MIG-99, an herb also known as feverfew
Riboflavin or vitamin B12
There is not enough evidence to suggest a role for aspirin or the NSAID indomethacin as way to stave off migraine headache.
Do You Need Migraine Prevention Treatment?
Mark W. Green, MD, says that anyone who has six or more migraine attacks a month or someone who has fewer migraines that don't respond to treatments is a potential candidate. Green is the director of the Center for Headache and Pain Medicine and professor of neurology and anesthesiology at the Mount Sinai School of Medicine in New York City.